Colorectal cancer screening and treatment: review of outcomes research
- PMID: 15504919
- DOI: 10.1093/jncimonographs/lgh005
Colorectal cancer screening and treatment: review of outcomes research
Abstract
Background: Colorectal cancer is the second leading cause of cancer deaths in the United States each year. Screening is effective in reducing colorectal cancer mortality; however, compliance with screening is poor, and factors associated with its compliance are poorly understood. The outcomes of treatment of colorectal cancer (surgery, radiation therapy, and chemotherapy) may have profound effects on quality of life (QOL). Furthermore, colorectal cancer screening and treatment may be expensive, and the costs are important from a policy perspective. This review examines patient-centered outcomes research related to colorectal cancer screening and treatment and outlines the work that has been done in several areas, including patient preferences, QOL, and economic analysis.
Methods: The literature on the health outcomes associated with colorectal cancer screening and treatment was reviewed. A MEDLINE search of English language articles published from January 1, 1990 through February 2001, was conducted and was supplemented by a review of references of obtained articles. Criteria for study inclusion were identified a priori. A standardized data abstraction form was developed. Summary statistical analyses were performed on the results.
Results: Six hundred eighty-six articles were selected for review. In total, 530 articles were excluded because they either did not include patient-centered outcomes, were duplicate articles, or could not be obtained. There were 156 articles included in the analysis; 67 addressed screening, 18 examined surveillance of high-risk groups, 22 concerned treatment of local disease, 10 examined treatment of local and metastatic disease, and 19 considered treatment of metastatic disease only. One study examined end-of-life care. In 19 studies, the phase of care was unspecified.
Conclusions: Standardized, disease-specific QOL instruments should be applied in clinical trials so that the results may be compared across different types of interventions. Valid and reliable methods that accurately capture patient preferences regarding screening and treatment should be developed.
Similar articles
-
Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.J Natl Cancer Inst Monogr. 2004;(33):78-101. doi: 10.1093/jncimonographs/lgh016. J Natl Cancer Inst Monogr. 2004. PMID: 15504921 Review.
-
Descriptive review of the literature on breast cancer outcomes: 1990 through 2000.J Natl Cancer Inst Monogr. 2004;(33):8-44. doi: 10.1093/jncimonographs/lgh003. J Natl Cancer Inst Monogr. 2004. PMID: 15504918 Review.
-
A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia.J Natl Cancer Inst Monogr. 2004;(33):102-25. doi: 10.1093/jncimonographs/lgh002. J Natl Cancer Inst Monogr. 2004. PMID: 15504922 Review.
-
Outcomes research in lung cancer.J Natl Cancer Inst Monogr. 2004;(33):56-77. doi: 10.1093/jncimonographs/lgh001. J Natl Cancer Inst Monogr. 2004. PMID: 15504920 Review.
-
Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127. Pediatrics. 2005. PMID: 15867026 Review.
Cited by
-
Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer.Am J Pathol. 2010 Apr;176(4):1619-28. doi: 10.2353/ajpath.2010.090467. Epub 2010 Feb 11. Am J Pathol. 2010. PMID: 20150437 Free PMC article.
-
Colorectal cancer: epidemiology, risk factors, and health services.Clin Colon Rectal Surg. 2005 Aug;18(3):133-40. doi: 10.1055/s-2005-916274. Clin Colon Rectal Surg. 2005. PMID: 20011296 Free PMC article.
-
N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer.Int J Oncol. 2022 Feb;60(2):14. doi: 10.3892/ijo.2022.5304. Epub 2022 Jan 11. Int J Oncol. 2022. PMID: 35014676 Free PMC article.
-
Barriers to colorectal cancer screening: physician and general population perspectives, New Mexico, 2006.Prev Chronic Dis. 2011 Mar;8(2):A35. Epub 2011 Feb 15. Prev Chronic Dis. 2011. PMID: 21324249 Free PMC article.
-
Previous cancer screening behavior as predictor of endoscopic colon cancer screening among women aged 50 and over, in NYC 2002.J Community Health. 2008 Feb;33(1):10-21. doi: 10.1007/s10900-007-9067-3. J Community Health. 2008. PMID: 18080204
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical